Redeye is growing more optimistic about the investment case in Oncopeptides after two news items this week: the inclusion of Pepaxti in the EHA-EMN guidelines and strong sales growth in Q2.
ANNONS
Redeye is growing more optimistic about the investment case in Oncopeptides after two news items this week: the inclusion of Pepaxti in the EHA-EMN guidelines and strong sales growth in Q2.